Monday, 12 April 2021

Doceree appoints Preetha Vasanji as Sr VP to helm Doceree Engage

05 March 2021 | News

Based in Mumbai, Vasanji brings over 20 years of experience from healthcare and pharmaceutical sector

Doceree has announced its foray into enterprise level network solution with Doceree Engage, appointing Preetha Vasanji as Senior Vice President to lead the vertical in India.

Based in Mumbai, Vasanji brings over 20 years of experience from healthcare and pharmaceutical sector. Before Doceree, she worked with McCann Health in the capacity of Senior VP and General Manager, Mumbai.

With Doceree Engage, the physician marketing platform has taken a leap from offering physician marketing solutions to a business segment of a conglomerate to an enterprise level. The focus of the programme will be on enterprise level multi-channel engagement and performance marketing.

“With Doceree Engage, we would work in close partnership with Business Heads/CXO and help bring about the desired cultural change within the organisation. From reach and RoI to creative standards and outcomes, Doceree Engage impacts every aspect of doctor engagement in the digital world,” said Dr Harshit Jain, Founder & CEO, Doceree.

The Doceree Engage model will leverage the technology core of Doceree, while also creating a strategic consulting role for the company.

Commenting on her new role, Vasanji said, “I am absolutely delighted to be a part of Doceree and the role it can play in fundamentally transforming the way physician marketing is done in the digital world. It is a fascinating play of technology and an astute sense of strategy to optimise outcomes. This medium is here to stay and will be an imperative part of every marketers plan co-existing with the offline world.”

“With Preetha’s enormous experience of healthcare and pharma advertising, we are expanding our capabilities in the market,” added Dr Jain.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls